Roche Bets $1B on Undisclosed Bispecific Targets: Platform Promise, Zero Clinical Proof

Roche Partners with Dualitas for Next-Gen Bispecifics

Roche has partnered with Dualitas Therapeutics in a deal potentially worth up to $1 billion to develop next-generation bispecific antibodies for immunological and inflammatory conditions. The agreement includes an upfront payment of $36.5 million to Dualitas, with additional funds allocated for research, development, and commercial milestones, plus tiered royalties on future product sales. Roche will leverage Dualitas’ proprietary DualScreen Bispecific Discovery Engine platform and will be responsible for all preclinical, regulatory, manufacturing, and commercial activities. This collaboration aims to expand Roche's expertise in bispecific therapies and explore novel target pairs.

• Strategic Collaboration for Bispecific Antibodies: Roche has entered a significant collaboration with Dualitas Therapeutics, focusing on the discovery and development of novel bispecific antibodies for immunological and inflammatory conditions. This partnership aims to leverage Dualitas' advanced platform to create therapies that target a broader range of biological pathways compared to existing bispecific approaches, which often focus on pre-determined target pairs.
• Financial Terms and Platform Access: The deal is structured with an upfront payment of $36.5 million to Dualitas, with the potential to reach $1 billion upon the achievement of various research, development, and commercial milestones. Dualitas will also receive tiered royalties on product sales. Roche gains exclusive access to Dualitas’ DualScreen Bispecific Discovery Engine platform, which is designed to screen over 300,000 bispecific combinations.
• Expansion of Roche's Bispecific Portfolio: This agreement underscores Roche's ongoing commitment to expanding its bispecific therapy pipeline. The company already has FDA-approved bispecifics like Columvi, Lunsumio, and Vabysmo, and has recently engaged in other substantial deals, including a $75 million upfront payment to Qyuns Therapeutics for a long-acting candidate and multi-billion dollar pacts with Hanmi Pharm, DualityBio, and Nurix Therapeutics.

Roche's Strategic Deepening in the Evolving Immunology Landscape

The treatment landscape for immunological and inflammatory conditions has undergone substantial transformation, driven by the expansion of both biologic and small-molecule therapeutic classes across multiple indications. Anti-TNF agents — infliximab and adalimumab — remain foundational, but newer biologics targeting distinct pathways have demonstrated meaningful clinical advances. Interleukin inhibitors such as ustekinumab and risankizumab have shown significant improvements in remission and mucosal healing in inflammatory bowel disease, while in moderate-to-severe plaque psoriasis, a 2026 network meta-analysis of 6,657 patients across 11 phase III randomized controlled trials established bimekizumab — a dual IL-17A/F inhibitor — as the highest-efficacy agent for achieving PASI 90 at week 16 (OR 170.04, 95% CI 104.33–277.14 vs. placebo), followed by risankizumab and guselkumab. In Crohn's disease, a Bayesian network meta-analysis identified risankizumab as having the lowest risk of adverse events (SUCRA 84.81), serious adverse events (SUCRA 94.23), and serious infections (SUCRA 79.73) during induction therapy, positioning it as a particularly compelling option for TNF antagonist-experienced patients alongside ustekinumab (SUCRA 86.19).

The JAK inhibitor class has emerged as a pivotal oral alternative across immune-mediated inflammatory diseases (IMIDs), with tofacitinib, baricitinib, upadacitinib, and filgotinib now approved across rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis by various regulatory agencies. Real-world multicenter data from 236 IBD patients treated with upadacitinib between January 2023 and September 2024 demonstrated that 76.8% of Crohn's disease patients achieved steroid-free remission at 12 weeks (p < 0.001) and 64.0% of ulcerative colitis patients achieved steroid-free remission at 8 weeks, underscoring its effectiveness in biologic-resistant cases. However, safety scrutiny has intensified: a systematic literature review informing the 2025 EULAR recommendations identified elevated venous thromboembolism risk with JAK inhibitors compared with biologic DMARDs — driven primarily by pulmonary embolism — and a higher herpes zoster risk relative to biologic DMARDs, though no consistent evidence of increased major adverse cardiovascular events was identified. These findings have prompted risk stratification frameworks to guide appropriate patient selection.

Looking ahead, the field is advancing on two parallel fronts: selectivity and delivery. Efforts to develop more isoform-selective JAK inhibitors — exemplified by deucravacitinib, a TYK2 inhibitor with a mechanistically distinct profile from conventional JAK inhibitors — aim to preserve efficacy while improving the safety margin. Simultaneously, nanotechnology-based drug delivery systems and HDAC inhibitors are showing early-phase promise in IBD. Dual therapy strategies combining two biologics or a biologic with a small molecule are also being explored for refractory IBD patients, with approximately 40% of patients remaining refractory to existing advanced therapies. Biosimilars to infliximab, adalimumab, and ustekinumab, alongside generic JAK inhibitors, have begun to address accessibility barriers — particularly relevant in low- and middle-income regions — while the integration of biomarkers and artificial intelligence into treatment algorithms represents the next frontier for precision IBD management.

Dualitas' DualScreen Engine: Unlocking Novel Bispecific Targets

Recent research has identified several promising therapeutic targets across immunological and inflammatory conditions, spanning innate immune sensors, receptor-level modulators, and transcriptional regulators. These targets are being pursued through diverse modalities — including small-molecule inhibitors, monoclonal antibodies, bispecific antibodies, and chimeric recombinant proteins — reflecting the breadth of mechanistic opportunities now under investigation.

• NLRP3 Inflammasome: The NLRP3 inflammasome, an innate immune sensor present in monocytes and macrophages, drives pathological inflammation through a cleavage cascade that releases proinflammatory cytokines IL-1β and IL-18 and induces pyroptosis. Its aberrant activation has been implicated in Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, gout, type 2 diabetes mellitus, cancer, and sensory hearing loss. Small-molecule inhibitors — including MCC950 as a proof-of-concept compound — are now in clinical trials, establishing that the inflammasome is druggable and prompting expanded drug development programs targeting additional inflammasome components.

• FcγRIIb (Inhibitory IgG Receptor): FcγRIIb is the only inhibitory IgG receptor, divided into subtypes FcγRIIb1, FcγRIIb2, and FcγRIIb3. It maintains immune balance by cross-linking with activated receptors to transduce intracellular inhibitory signals, negatively regulating both innate and adaptive immunity. Abnormal FcγRIIb expression is associated with autoimmune and infectious diseases, and it is being explored through monoclonal antibodies, chimeric recombinant proteins, and bispecific antibodies that modulate activation of B lymphocytes, monocytes, mast cells, and basophils.

• CD28 and ICOS Immune Checkpoints: CD28 and ICOS regulate T-cell activation, differentiation, and immune tolerance; their dysregulation contributes to cancer immune evasion, autoimmune diseases, and chronic inflammation. Therapeutic approaches include CTLA-4-Ig fusion proteins (abatacept, belatacept) for autoimmune diseases, ICOS agonists (feladilimab, vopratelimab) to enhance anti-tumor immunity, and bispecific CD28-engaging antibodies (CD28xCD3, CD28xPSMA) for cancer immunotherapy.

• B Lymphocytes as Therapeutic Targets: B cells are established targets in autoimmune conditions including multiple sclerosis, type I diabetes, systemic lupus erythematosus, and rheumatoid arthritis. Cutting-edge modalities include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, chimeric antigen receptor-T cells, and small-molecule inhibitors, with emerging efforts focused on selectively eliminating pathogenic autoreactive B cells and silencing B-cell function without depletion.

• Interferon Regulatory Factor 5 (IRF5): IRF5 is a key transcription factor that drives macrophages toward a proinflammatory phenotype by regulating cytokine and chemokine expression, modulates B-cell maturity and antibody production, and drives type I interferon expression in antiviral responses. Polymorphic mutations at the human Irf5 locus confer susceptibility to systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease, and modulation of IRF5 activity and expression is hypothesized to provide therapeutic benefits.

• ATG16L1 and the cGAS-STING Pathway in Intestinal Inflammation: ATG16L1, an inflammatory bowel disease risk gene, critically orchestrates IL-22 signaling in the intestinal epithelium. IL-22 stimulation leads to transient ER stress and subsequent activation of STING-dependent type I interferon signaling, which amplifies epithelial TNF production and contributes to necroptotic cell death. Therapeutic blockade of type I interferon signaling ameliorates IL-22-induced ileal inflammation in Atg16l1 deficient mice, identifying the cGAS-STING axis as a candidate target in IBD.

Addressing Persistent Unmet Needs in Immunological and Inflammatory Care

Recent research across immunological and inflammatory conditions highlights persistent gaps in disease control, particularly among patients who are refractory to established therapies, steroid-dependent, or inadequately served by existing mechanistic approaches. Across severe asthma, autoimmune vasculitis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus, clinical and translational work is converging on populations where standard-of-care regimens fall short.

• Biologic-experienced and treatment-refractory severe asthma: In a real-world German cohort of 129 patients initiating tezepelumab, prior treatment with other biologics was associated with inferior treatment response — underscoring the unmet need in patients who have cycled through multiple biologic lines. Notably, tezepelumab demonstrated a treatment response (per Biologic Asthma Response Score) of 80.8% across T2-high and T2-low, eosinophilic and non-eosinophilic phenotypes, with a median reduction in oral corticosteroid dose of -5 mg [-10; 0] among long-term OCS-dependent patients.

• Steroid-dependent rare eosinophilic diseases: Patients with ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) who remain refractory or steroid-dependent despite conventional immunosuppression represent a critically underserved population. A real-world case series reported that benralizumab produced rapid, sustained eosinophil depletion, enabled glucocorticoid discontinuation in two of three patients, and achieved complete resolution of cardiac lesions on MRI in one patient after six months — findings the authors characterise as preliminary and requiring confirmation in larger prospective studies.

• Refractory inflammatory bowel disease and concomitant extraintestinal manifestations: Patients with IBD refractory to conventional therapy, or those with co-occurring immune-mediated inflammatory diseases, represent a population with limited treatment options. A retrospective multicenter Chinese study of 47 such patients receiving dual-targeted therapy (biologics combined with small molecules) reported clinical response in 78.7% and clinical remission in 57.4% at a median follow-up of 13.0 months, with serious adverse events in only 2.1% of patients. Separately, combined FMT and infliximab in nine refractory Crohn's disease patients achieved week-4 response in six, with all six attaining clinical and endoscopic remission by week 14.

• JAK inhibitor-inadequate responders in rheumatoid arthritis: Patients with RA who fail to achieve low disease activity on JAK inhibitors (JAKi-IR) — identified at a rate of 31.8% (138/434) in the FIRST registry — represent a distinct and growing population. Registry data suggest that cycling to a second JAK inhibitor produced greater CDAI improvement and higher remission rates at 26 weeks compared with switching to a biologic DMARD, with no differences in safety or retention, pointing to an underexplored sequencing strategy in this population.

• Treatment-resistant systemic lupus erythematosus: A subset of SLE patients develops manifestations inadequately controlled by multiple standard immunosuppressants. CAR-T cell therapy targeting B cell antigens such as CD19 or BCMA is emerging as an investigational approach in this population, with early case series reporting remission and serologic improvements; however, long-term durability, relapse risk, and cost-effectiveness remain unestablished and require confirmation in larger controlled trials.

• Mild-to-moderate atopic dermatitis requiring steroid-sparing topical options: The limitations of long-term corticosteroid and calcineurin inhibitor use create an unmet need for effective, well-tolerated topical alternatives. In a phase 3 evaluation, twice-daily ivarmacitinib ointment (a topical JAK1 inhibitor) at 1% achieved an IGA response in 26.2% versus 10.6% for vehicle (P = 0.0013) and EASI-75 in 45.1% versus 17.9% (P < 0.0001) at week 8, with pruritus relief within 48 hours and no skin atrophy or application-site irritation observed through week 52.

Roche's Next-Gen Bispecific Bet for Immunology Leadership

The pharmaceutical landscape is increasingly shaped by the advent of bispecific antibodies, a class of therapeutics designed to engage two distinct targets simultaneously. Roche, a pioneer in this field with its established CrossMab technology, has already demonstrated the transformative potential of this modality through agents like faricimab, which targets VEGF-A and Ang-2 for retinal diseases, and mosunetuzumab, a CD20xCD3 T-cell engager showing impressive complete response rates in follicular lymphoma. This new partnership with Dualitas Therapeutics, a deal potentially worth up to $1 billion, signals Roche's strategic intent to push the boundaries further, moving into the 'next-generation' of bispecific design.

This collaboration is particularly focused on immunological and inflammatory conditions, an area ripe for innovation given the multi-factorial nature of diseases like rheumatoid arthritis or ulcerative colitis. Research indicates that simultaneously blocking multiple pathogenic cytokines, such as BAFF and IL-17A or TNF and IL-17A, can offer enhanced therapeutic effects compared to single-target approaches. Dualitas' proprietary DualScreen Bispecific Discovery Engine is expected to unlock novel target pairs and overcome some of the inherent challenges in bispecific development.

However, the path to successful next-generation bispecifics is not without its hurdles:

• Engineering Complexity: Ensuring molecular stability, preventing aggregation, and achieving optimal in vivo target engagement remain significant challenges, as highlighted by past development efforts.

• Safety Profile: While highly effective, bispecifics can induce immune-related adverse events, such as cytokine release syndrome, which requires careful management and dose optimization during clinical development.

• High Investment and Competition: The substantial financial commitment underscores the high-risk, high-reward nature of this field, where numerous players are vying for innovative multi-targeting solutions.

Ultimately, this strategic alliance positions Roche to explore novel mechanisms and potentially deliver more potent and durable therapies for patients suffering from chronic inflammatory diseases. Success will depend on the ability to translate the promise of next-generation bispecific engineering into clinically superior and well-tolerated medicines, solidifying Roche's leadership in this dynamic therapeutic space.